Sanofi Under Fire by Senate Panel For Competition Delaying Tactics


By Pharmaceutical Manufacturing Staff

May 26, 2011

Sanofi contributed more than $5 million to two medical groups and a researcher as part of a coordinated campaign to delay the approval of generic alternatives to Lovenox, the company's blockbuster blood-thinner, a U.S. Senate Finance Committee investigation has found.

Read more of this story from here.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments